As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order Anthem shareholders OK rebrand as Elevance Health FDA clears NeuroMetrix’s wearable neuromodulator as first non-drug fibromyalgia treatment Amgen celebrates 25 years of deCODE Genetics as partnership evolves from discovery to development Catalent throws down $175M on yet another manufacturing expansion XACT's needle-guiding robot scores FDA clearance for ablation procedures Enanta sinks to multiyear low as phase 2b RSV trial flames out Transcarent launching behavioral health offering After Big Pharma pulls back in Russia, Dr. Reddy's says business is booming Nanobiotix scales down R&D plan, freezes hiring to close gap between cash runway and phase 3 data Brain-computer interface zooms ahead in helping paralysis patient drive again HHS commits $300M to global accelerator targeting antibiotic-resistant bacteria Featured Story | By Angus Liu A monkeypox outbreak is emerging in several regions, and at least one European country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe or Jynneos in the U.S. read more |
| |
|---|
|
Top Stories By Paige Minemyer The name combines the concepts of "elevate" and "advance," Anthem said, to reflect its efforts to grow beyond being a health insurance company. read more By Andrea Park With the FDA’s nod, Massachusetts-based NeuroMetrix plans to launch the wearable, prescription-only Quell system as a fibromyalgia treatment in the fourth quarter of this year. read more By Max Bayer Amgen and deCODE Genetics say the future of their partnership is in the clinic, touting the impact gene hunting has on drug development. The aspirations were relayed at deCODE's belated 25th-anniversary event. read more By Fraiser Kansteiner Production powerhouse Catalent has unveiled yet another manufacturing expansion, this time at a massive oral medicines plant that already doubled in size back in 2015. read more By Conor Hale This includes image-guided operations to burn out or freeze clumps of tumor cells without the need for open surgery. The new green light adds to the robot’s already broad clearance for performing CT-guided percutaneous procedures. read more By Nick Paul Taylor Enanta Pharmaceuticals’ bid to treat low-risk respiratory syncytial virus (RSV) patients has gone off the rails. The failure of the phase 2b trial of N-protein inhibitor EDP-938 in the population sent Enanta’s stock to its lowest ebb since 2017 but failed to extinguish the biotech’s belief in the prospect in other settings. read more By Paige Minemyer Transcarent is rolling out a behavioral health offering that aims to boost access to care, a major challenge for people with mental health needs. read more By Kevin Dunleavy Generic drugmaker Dr. Reddy’s Laboratories says it plans to launch new products in Russia after its business there delivered a whopping 70% revenue increase. read more By Nick Paul Taylor Nanobiotix has joined the ranks of biotechs that are trying to eke out their cash reserves. With its cash down to 70.6 million euros ($74 million) and its phase 3 solid tumor trial still two years away from interim data, the French biotech is enacting a suite of changes intended to save up to 15 million euros a year. read more By Andrea Park Nearly a decade after a car accident left him paralyzed from the waist down, Florida resident German Aldana Zuniga got back behind the wheel—thanks to a microchip implanted in his brain. read more By Dave Muoio HHS and partners' new funds will support CARB-X, the world's largest public-private accelerator supporting early-stage therapies and diagnostics for antibiotic-resistant infections. read more | 